New Patented Medicines Reported to PMPRB

Up to date as of March 30, 2021

Search by:

to

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.


YearCompanyBrand NameChemical NameDINTherapeutic UseDate of First SaleStatus
2019AbbvieOrilissa - 200 mg/tabletelagolix02481340pain associated with endometriosis24 May 2019Within Guidelines
2019AbbvieSkyrizi - 75 mg/syringerisankizumab02487454moderate-to-severe plaque psoriasis13 May 2019Within Guidelines
2019Akcea Therapeutics CanadaTegsedi - 284 mg/syringeinotersen02481383hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)12 Nov 2019VCU
2019Alnylam Pharmaceuticals, Inc.Onpattro - 2 mg/mLpatisiran02489252hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)04 Oct 2019VCU
2019Amgen Canada Inc.Evenity - 105 mg/syringeromosozumab02489597osteoporosis12 Aug 2019Within Guidelines
2019Astrazeneca Canada Inc.Calquence - 100 mg/capsuleacalabrutinib02491788cancer02 Oct 2019Within Guidelines
2019Bausch Health, Canada Inc.Vyzulta - 0.24 mg/mLlatanoprostene bunod02484218intraocular pressure (IOP)17 May 2019Within Guidelines
2019Bayer Inc.Vitrakvi - 20 mg/mLlarotrectinib02490331cancer04 Sep 2019Within Guidelines
2019Biogen Canada Inc.Spinraza - 2.4 mg/mLnusinersen024656635q Spinal Muscular Atrophy (SMA)29 Aug 2017Within Guidelines
2019Biomarin Pharmaceutical Canada Inc.Brineura - 30 mg/mLcerliponase alfa02484013neuronal ceroid lipofuscinosis type 2 (CLN2)18 Mar 2019Within Guidelines
2019CSL Behring Canadda Inc.Idelvion - 1000 IU/vialcoagulation factor IX (recombinant), albumin fusion protein (RIX-FP)02451352hemophilia B04 Jul 2019Subject to Investigation
2019Eisai LimitedLenvima - 12 mg/daylenvatinib mesylate02484129cancer29 Oct 2019Within Guidelines
2019Eisai LimitedLenvima - 4 mg/daylenvatinib mesylate02484056cancer29 Oct 2019Within Guidelines
2019Eli Lilly Canada Inc.Emgality - 120 mg/mLgalcanezumab02491060migraine07 Oct 2019Subject to Investigation
2019Eli Lilly Canada Inc.Emgality - 120 mg/mLgalcanezumab02491087migraine02 Oct 2019Subject to Investigation
2019Eli Lilly Canada Inc.Verzenio - 100 mg/tabletabemaciclib02487101cancer03 Jul 2019Within Guidelines
2019Eli Lilly Canada Inc.Verzenio - 150 mg/tabletabemaciclib02487128cancer03 Jul 2019Within Guidelines
2019Eli Lilly Canada Inc.Verzenio - 200 mg/tabletabemaciclib02487136cancer03 Jul 2019Within Guidelines
2019Eli Lilly Canada Inc.Verzenio - 50 mg/tabletabemaciclib02487098cancer03 Jul 2019Within Guidelines
2019Galderma Canada Inc.Aklief - 50 mcg/gramtrifarotenetrifarotneacne28 Nov 2019Within Guidelines
2019Glaxosmithkline Inc.Engerix-B - 1 N.A./dosehepatitis B surface antigen (recombinant)02487039hepatitis B18 Nov 2019Within Guidelines
2019Glaxosmithkline Inc.Engerix-B Pediatric - 20 mcg/mLhepatitis B surface antigen (recombinant)02487020hepatitis B07 Oct 2019Within Guidelines
2019HLS Therapeutics Inc.Vascepa - 1 g/capsuleicosapent ethyl02495244cardiovascular events15 Nov 2019Does Not Trigger Investigation
2019Hoffman-La Roche LimitedTecentriq - 60 mg/mLatezolizumab02492393cancer16 Oct 2019Within Guidelines
2019Hoffman-La Roche LimitedActemra - 162 mg/syringetocilizumab02483327rheumatoid arthritis15 Jan 2019Within Guidelines
2019Hoffman-La Roche LimitedHemlibra - 105 mg/vialemicizumab02479656hemophilia A14 May 2019Within Guidelines
2019Hoffman-La Roche LimitedHemlibra - 150 mg/mLemicizumab02479664hemophilia A14 May 2019Within Guidelines
2019Hoffman-La Roche LimitedHemlibra - 60 mg/vialemicizumab02479648hemophilia A14 May 2019Within Guidelines
2019Hoffman-La Roche LimitedHemlibra 30 mg/mLemicizumab02479621hemophilia A14 May 2019Within Guidelines
2019Ipsen Biopharmaceuticals Canada Inc.Xermelo - 250 mg/tablettelotristat ethyl02481553refractory carcinoid syndrome diarrhea07 Dec 2018Within Guidelines
2019Janssen Inc.Tremfya One-Press - 100 mg/mLguselkumab02487314plaque psoriasis21 May 2019Within Guidelines
2019Medexus Inc.Metoject Subcutaneous - 10 mg/syringemethotrexate (methotrexate sodium)02454831psoriasis/psoriatic arthritis and rheumatoid arthritis01 Oct 2019Within Guidelines
2019Medexus Inc.Metoject Subcutaneous - 12.5 mg/syringemethotrexate (methotrexate sodium)02454750psoriasis/psoriatic arthritis and rheumatoid arthritis01 Oct 2019Within Guidelines
2019Merck Canada Inc.Delstrigo 100/300/300 - 700 mg/tabletdoravirine/lamivudine/tenofovir disoproxil fumarate02482592human immunodeficiency virus-1 (HIV-1)10 Dec 2018Within Guidelines
2019Merck Canada Inc.Belsomra - 10 mg/tabletsuvorexant02483513insomnia18 Apr 2019Within Guidelines
2019Merck Canada Inc.Belsomra - 15 mg/tabletsuvorexant02483521insomnia18 Apr 2019Within Guidelines
2019Merck Canada Inc.Belsomra - 20 mg/tabletsuvorexant02483548insomnia18 Apr 2019Within Guidelines
2019Mitsubishi Tanabe Pharma CanadaRadicava - 30 mg/doseedaravone02475472amyotrophic lateral sclerosis (ALS)29 Oct 2019Under Review
2019Novartis Pharmaceuticals Canada Inc.Aimovig - 140 mg/mLerenumab02487306migraine22 May 2019VCU
2019Novartis Pharmaceuticals Canada Inc.Aimovig - 70 mg/mLerenumab02479613migraine04 Dec 2018VCU
2019Novartis Pharmaceuticals Canada Inc.Gilenya - 0.25 mg/capsulefingolimod hydrochloride02482533multiple sclerosis (MS)03 Jan 2019Within Guidelines
2019Novartis Pharmaceuticals Canada Inc.Tasigna - 50 mg/capsulenilotinib hydrochloride monohydrate02481715Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)17 May 2019Within Guidelines
2019Novartis Pharmaceuticals Canada Inc.Signifor Lar - 10 mg/vialpasireotide02480425acromegaly and Cushing's disease30 May 2019Does Not Trigger Investigation
2019Novartis Pharmaceuticals Canada Inc.Signifor Lar - 30 mg/vialpasireotide02480433acromegaly and Cushing's disease30 May 2019Does Not Trigger Investigation
2019Novartis Pharmaceuticals Canada Inc.Kymriah - 1 N.A./dosetisagenlecleucel02480514cancer24 May 2019Within Guidelines
2019Novo Nordisk Canada Inc.Xultophy - 100 unit/mLinsulin degludec/liraglutide02474875type 2 diabetes mellitus15 Jun 2018Under Review
2019Paladin Labs Inc.Envarsus PA - 0.75 mg/tablettacrolimus02485877prophylaxis of organ rejection17 Apr 2019Within Guidelines
2019Paladin Labs Inc.Envarsus PA - 1 mg/tablettacrolimus02485885prophylaxis of organ rejection17 Apr 2019Within Guidelines
2019Paladin Labs Inc.Envarsus PA - 4 mg/tablettacrolimus02485893prophylaxis of organ rejection17 Apr 2019Within Guidelines
2019Paladin Labs Inc.Wakix - 20 mg/tabletpitolisant-448narcolepsy30 Nov 2019Under Review
2019Paladin Labs Inc.Wakix - 5 mg/tabletpitolisant-449narcolepsy30 Nov 2019Under Review
2019Pfizer Canada Inc.Lorbrena - 100 mg/tabletlorlatinib02485974cancer23 Apr 2019Within Guidelines
2019Pfizer Canada Inc.Lorbrena - 25 mg/tabletlorlatinib02485966cancer23 Apr 2019Within Guidelines
2019Pfizer Canada Inc.Xeljanz - 10 mg/tablettofacitinib02480786rheumatoid arthritis (RA)30 Jan 2019Within Guidelines
2019Pfizer Canada Inc.Vizimpro - 15 mg/tabletdacomitinib02486024cancer23 Apr 2019Within Guidelines
2019Pfizer Canada Inc.Vizimpro - 30 mg/tabletdacomitinib02486032cancer23 Apr 2019Within Guidelines
2019Pfizer Canada Inc.Vizimpro - 45 mg/tabletdacomitinib02486040cancer23 Apr 2019Within Guidelines
2019Pfizer Canada Inc.Xyntha Solofuse - 500 unit/syringemoroctocog alfa02374064hemophilia A01 Oct 2019Within Guidelines
2019Sanofi-Aventis Canada Inc.Dupixent - 200 mg/syringedupilumab02492504atopic dermatitis29 Nov 2019Within Guidelines
2019Santen SASVerkazia - 1 mg/mLcyclosporine02484137severe vernal keratoconjunctivitis26 Apr 2019Within Guidelines
2019Swedish Orphan Biovitrum, SOBI ABGamifant - 10 mg/vialemapalumabhemophagocytic lymphohistiocytosis (HLH)30 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 10 mg/tabletlisdexamfetamine dimesylate02490226Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 20 mg/tabletlisdexamfetamine dimesylate02490234Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 30 mg/tabletlisdexamfetamine dimesylate02490242Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 40 mg/tabletlisdexamfetamine dimesylate02490250Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 50 mg/tabletlisdexamfetamine dimesylate02490269Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019Takeda Canada Inc.Vyvanse - 60 mg/tabletlisdexamfetamine dimesylate02490277Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED)06 Aug 2019Subject to Investigation
2019ThromboGenics N.V.Jetrea - 1.25 mg/mLocriplasmin02452154vitreomacular adhesion (VMA)08 May 2019Within Guidelines
2019UCB Canada Inc.Brivlera - 10 mg/mLbrivaracetam02452995epilepsy24 Jan 2019Within Guidelines
2019Ultragenyx Pharmaceuticals Inc.Crysvita - 10 mg/mLburosumab02483629X-linked hypophosphataemia (XLH)28 Jan 2019Within Guidelines
2019Ultragenyx Pharmaceuticals Inc.Crysvita - 20 mg/mLburosumab02483637X-linked hypophosphataemia (XLH)28 Jan 2019Subject to Investigation
2019Ultragenyx Pharmaceuticals Inc.Crysvita - 30 mg/mLburosumab02483645X-linked hypophosphataemia (XLH)28 Jan 2019Subject to Investigation
2019Valeo PharmaOnstryv - 100 mg/tabletsafinamide02484668Parkinson's disease08 Jul 2019Within Guidelines
2019Valeo PharmaOnstryv - 50 mg/tabletsafinamide02484641Parkinson's disease08 Jul 2019Within Guidelines
2019Verity Pharmaceuticals Inc.Zeulide Depot - 22.5 mg/vialleuprolide acetate02462699cancer08 Oct 2019Subject to Investigation
2019Verity Pharmaceuticals Inc.Zeulide Depot - 3.75 mg/doseleuprolide acetate02429977cancer08 Oct 2019Subject to Investigation
2019Vertex Pharmaceuticals Canada Inc.Orkambi 100/125 - 225 mg/granulelumacaftor/ivacaftor02483831cystic fibrosis (CF) and homozygous for the F508del mutation14 Dec 2018Under Review
2019Vertex Pharmaceuticals Canada Inc.Orkambi 150/188 - 338 mg/granulelumacaftor/ivacaftor02483858cystic fibrosis (CF) and homozygous for the F508del mutation14 Dec 2018Under Review
2019Vifor International AGVelphoro - 500 mg/tabletiron (sucroferric oxyhydroxide)02471574renal disease20 Nov 2019Does Not Trigger Investigation
2019Vifor International AGVeltassa - 16.8 g/sachetpatiromer02481367kidney disease27 Nov 2019Subject to Investigation
2019Viiv Healthcare UlcDovato 50/300 - 350 mg/tabletdolutegravir/lamivudine02491753HIV11 Sep 2019Within Guidelines